Sensex, Nifty Set To Extend Losses As Trump Slaps 100% Tariff On Pharma

Indian shares are poised for further declines, extending a five-session losing streak, as President Trump announced new tariffs on various imports, including 100% on branded drugs and 25% on heavy-duty trucks, adding to existing concerns over U.S.-India trade and H-1B visas. This bearish sentiment is compounded by foreign institutional investors net selling Rs 4,995 crore and broader global market weakness, with the S&P 500 declining for a third consecutive session amidst valuation concerns and fading hopes for aggressive Fed rate cuts despite strong U.S. Q2 GDP growth.

Analysis

Indian equity markets are positioned for continued weakness, extending a five-day losing streak after U.S. President Trump announced a new wave of tariffs, including a prohibitive 100% tariff on branded drugs and 25% on heavy-duty trucks. This direct trade escalation compounds existing market anxieties over U.S.-India trade negotiations and H-1B visa policies. Capital flows reveal a critical divergence, with foreign institutional investors (FIIs) net selling Rs 4,995 crore, a bearish signal that was almost entirely offset by domestic institutional investors (DIIs) purchasing Rs 5,103 crore, suggesting domestic conviction is currently buffering foreign flight. This domestic fragility is set against a broader risk-off global environment, with the S&P 500 marking its longest slide in a month. Paradoxically, strong U.S. economic data, including the fastest Q2 GDP growth in nearly two years, is weighing on sentiment by diminishing expectations for aggressive Federal Reserve rate cuts, thereby pressuring equity valuations, particularly in the tech sector. Meanwhile, rising oil prices, stemming from geopolitical conflict impacting Russian exports, introduce an additional inflationary risk to the global outlook.

Key Decisions for Investors

• Investors should re-evaluate exposure to Indian export-oriented sectors, particularly pharmaceuticals and heavy manufacturing, given the direct and significant threat from newly announced U.S. tariffs.
• Monitor the divergence between foreign institutional selling and domestic institutional buying in India, as sustained foreign outflows could overwhelm local support and signal further downside for the Sensex and Nifty.
• Exercise caution with rate-sensitive U.S. growth and technology stocks, as robust economic data is reducing the likelihood of aggressive Fed rate cuts, thereby challenging the high-valuation narrative.
• Consider the portfolio impact of rising oil prices, which, driven by geopolitical supply disruptions, could act as an inflationary headwind that complicates central bank policy and erodes corporate margins.